Targeting HER2: A report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials

mAbs

Volumn 2, Issue 5, 2010, Pages 550-564

  Milenic, Diane E ^a   Wong, Karen J ^b   Baidoo, Kwamena E ^a   Nayak, Tapan K ^a   Regino, Celeste A S ^b   Garmestani, Kayhan ^a   Brechbiel, Martin W ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HER2; Monoclonal antibody; Radioimmunodiagnosis; Radioimmunotherapy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN A375; CELL STRAIN SKOV 3; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG CONJUGATION; GAMMA SCINTIGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; ISOTHIOCYANATES; MALE; MELANOMA; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958557527     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.5.13054     Document Type: Article

References (69)

1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45.
2. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-70.
3. Shepard HM, Jin P, Slamon D, Pirot Z, Maneval DC. Herceptin. In: Y. Chernajovsky, Nissim A, Ed(s). Therapeutic Antibodies. Handbook of Experimental Pharmacology. Berlin Heidelberg: Springer-Verlag 2008; 183-219.
4. Ellis LM, Hicklin DJ. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res 2009; 15:7471-8.
5. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009; 15:7479-91.
6. Azzam EI, de Toledo SM, Little JB. Stress signaling from irradiated to non-irradiated cells. Curr Cancer Drug Targets 2004; 4:53-64.
7. Prise KM, Folkard M, Michael BD. Bystander responses induced by low LET radiation. Oncogene 2003; 22:7043-9.
8. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9:253-66.
9. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52:3402-8.
10. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, et al. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004; 10:4489-97.
11. Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem 2005; 16:1117-25.
12. 111In-DTPA-trastuzumab. Br J Pharmacol 2004; 143:99-106.
13. Milenic D, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease. Clin Cancer Res 2004; 23:7834-41.
14. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 2007; 13:1926-35.
15. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005; 20:557-68.
16. Palm S, Back T, Claesson I, Danielsson A, Elgqvist J, Frost S, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys 2007; 69:572-9.
17. Palm S, Enmon RM Jr, Matei C, Kolbert KS, Xu S, Zanzonico PB, et al. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 2003; 44:1148-55.
18. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005; 32:51-8.
19. Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000; 11:327-34. (Pubitemid 30324898)
20. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43:2046-51.
21. 89Zr- trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009; 50:974-81.
22. 111In labeled Herceptin. Nucl Med Biol 2002; 29:599-606.
23. Gee MS, Upadhyay R, Bergquist H, Alencar H, Reynolds F, Maricevich M, et al. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology 2008; 248:925-35.
24. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 2009; 36:81-93.
25. Niu G, Li Z, Cao Q, Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA- trastuzumab. Eur J Nucl Med Mol Imaging 2009; 36:1510-9.
26. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24:2276-82. (Pubitemid 46630657)
27. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005; 65:1471-8. (Pubitemid 40270176)
28. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006; 47:793-6. (Pubitemid 46768442)
29. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22:701-6. (Pubitemid 38702826)
30. Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer and ovarian cancer. Semin Oncol 2000; 27:53-63.
31. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45:457-61.
32. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5:953-62.
33. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19:554-68.
34. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28:13-9.
35. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992; 52:1916-23.
36. Elgqvist J, Andersson H, Haglund E, Jensen H, Kahu H, Lindegren S, et al. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother Radiopharm 2009; 24:509-13.
37. 131I-labeled counterparts. Cancer Biother Radio 1996; 11:133-44.
38. Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, et al. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 2009; 15:6709-15.
39. Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin Cancer Res 1999; 5:2748-55.
40. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. P Natl Acad Sci USA 2007; 104:4071-6.
41. Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, et al. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res 2007; 13:3286-92.
42. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 1994; 35:882-9.
43. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002; 29:431-42.
44. Milenic DE, Roselli M, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother Radio 2001; 16:133-46.
45. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radio 2008; 23:619-31.
46. Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, et al. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol 2009; 157:1541-8.
47. Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res 1987; 47:6528-31. (Pubitemid 18019649)
48. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, et al. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 1988; 26:187-201.
49. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999; 40:1935-46.
50. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586-92.
51. 18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008; 35:1008-18.
52. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50:417-25.
53. Ogawa M, Regino CA, Seidel J, Green MV, Xi W, Williams M, et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem 2009; 20:2177-84.
54. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007; 48:1501-10.
55. Xu H, Eck PK, Baidoo KE, Choyke PL, Brechbiel MW. Toward preparation of antibody-based imaging probe libraries for dual-modality positron emission tomography and fluorescence imaging. Bioorg Med Chem 2009; 17:5176-81.
56. Esteban JM, Schlom J, Gansow OA, Atcher RW, Brechbiel MW, Simpson DE, et al. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1987; 28:861-70.
57. Lorimore SA, Coates PJ, Wright EG. Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation. Oncogene 2003; 22:7058-69.
58. Tom BH, Rutzky LH, Jakstys MH. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro 1976; 12:180-91.
59. Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution and enhanced antitumor activity. Cancer Res 2004; 64:1460-7. (Pubitemid 38235617)
60. Cook JA, Choudhuri R, Degraff W, Gamson J, Mitchell JB. Halofuginone enhances the radiation sensitivity of human tumor cell lines. Cancer Lett 289:119-26.
61. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans- CyDTPA. Bioorg Med Chem 1997; 5:1925-34.
62. Garmestani K, Yao Z, Zhang M, Wong K, Park CW, Pastan I, et al. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol 2001; 28:409-18. (Pubitemid 32521000)
63. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent 1951; 193:265-75.
64. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992; 3:342-5.
65. Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis JS, et al. Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl Med Biol 2005; 32:891-7.
66. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80:849-57.
67. Xu H, Baidoo K, Gunn AJ, Boswell CA, Milenic DE, Choyke PL, et al. Design, synthesis and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem 2007; 50:4759-65. (Pubitemid 47463248)
68. 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts. Nucl Med Biol 1993; 20:955-62.
69. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, et al. PET imaging of HER1-expressing xenografts in mice with (86)Y-CHX-A″-DTPA- cetuximab. Eur J Nucl Med Mol Imaging 2010; 37:1368-76.